培高利特开放治疗对三环类及杂环类抗抑郁药耐药的抑郁症
Open pergolide treatment of tricyclic and heterocyclic antidepressant-resistant depression.
作者信息
Izumi T, Inoue T, Kitagawa N, Nishi N, Shimanaka S, Takahashi Y, Kusumi I, Odagaki Y, Denda K, Ohmori T, Koyama T
机构信息
Department of Psychiatry, Hokkaido University School of Medicine, North 15, West 7, Kita-ku, 060-8638, Sapporo, Japan.
出版信息
J Affect Disord. 2000 Dec;61(1-2):127-32. doi: 10.1016/s0165-0327(99)00199-8.
BACKGROUND
Recently, a dopamine hypothesis of depression was put forward, and several studies have demonstrated that direct and indirect dopamine agonists have antidepressant effects.
METHODS
Using Clinical Global Impressions, we evaluated the efficacy of 4-week treatment of pergolide as an antidepressant adjuvant involving 20 unipolar depressed patients who were refractory to standard treatment with antidepressants.
RESULTS
One patients (5%) were very much improved, seven (35%) much improved, four (20%) minimally improved, six (30%) no change or worse, and two (10%) not assessed. There was no significant difference in any clinical factors between the pergolide responder and non-responder group.
LIMITATIONS
This study was a non-blind open trial, and pergolide was added to tricyclic and heterocyclic antidepressants.
CONCLUSION
Pergolide may be useful as an antidepressant adjuvant, suggesting a potential role for dopamine-2 stimulation in the antidepressant response.
背景
最近，提出了抑郁症的多巴胺假说，并且多项研究已证明直接和间接多巴胺激动剂具有抗抑郁作用。
方法
使用临床总体印象量表，我们评估了培高利特作为抗抑郁辅助药物对20名对标准抗抑郁药治疗无效的单相抑郁症患者进行4周治疗的疗效。
结果
1名患者（5%）显著改善，7名（35%）明显改善，4名（20%）稍有改善，6名（30%）无变化或病情恶化，2名（10%）未评估。培高利特反应者和无反应者组之间在任何临床因素上均无显著差异。
局限性
本研究为非盲开放试验，且培高利特被添加到三环和杂环抗抑郁药中。
结论
培高利特可能作为抗抑郁辅助药物有用，提示多巴胺-2刺激在抗抑郁反应中具有潜在作用。
Zotero 插件